The MBRC brings together expertise from across the city to accelerate new discoveries through translational research that will improve health.
The MBRC is a partnership between Central Manchester University Hospitals NHS Foundation Trust, The University of Manchester, The Christie NHS Foundation Trust, Salford Royal NHS Foundation Trust, and University Hospital of South Manchester NHS Foundation Trust.
Supported by the Manchester Academic Health Science Centre, the MBRC will help clinicians to move towards more proactive approach to medicine by applying P4 principles:
- Prevent disease;
- Predict disease progression;
- Personalise treatment pathways;
- Empower patients to Participate in their healthcare
The NIHR has awarded £28.5m over five years from April 2017, to fund research posts and biomedical studies in the following areas:
Theme 1: Targeted Therapy for better patient outcomes in Musculoskeletal Diseases - Treat Smarter
Lead: Professor Anne Barton
Musculoskeletal disorders, such as arthritis and connective tissue diseases, account for over 20% of all GP consultations and are the second most common cause of disability worldwide. Building on the work of our NIHR Manchester Musculoskeletal Biomedical Research Unit, the BRC will focus on strategies to prevent arthritis developing in the first place. We are also developing new treatment approaches to arthritis in adults and children and new tests to improve our ability to personalise treatments used.
Theme 2: Hearing health
Lead: Professor Kevin Munro
Hearing loss will soon be the 7th largest global disease burden. It represents a major public health issue with substantial economic and societal costs. The BRC is focused on the rapid adoption of discoveries into routine clinical practice to improve health and wellbeing, reduce inequalities and provide value for money. The BRC will help deliver effective and efficient hearing health across the lifespan – from preventing potentially devastating inherited deafness through to age-related deafness.
Theme 3: Respiratory medicine
Lead: Professor Jorgen Vestbo
Respiratory diseases are the third most common cause of death and the second most common cause of hospital admissions in the UK. The BRC will build a better understanding of the underlying causes of respiratory conditions and test new drug compounds aimed at novel targets to modify the disease processes involved and improve symptom control in patients. Research will focus on earlier diagnosis and more targeted treatment, to maximise the likelihood of a good treatment response for an individual whilst minimising the risks of harm from therapies such as antimicrobial resistance.
Theme 4: Dermatology - cutaneous inflammation and repair
Lead: Professor Chris Griffiths
Skin conditions and poor wound healing have a considerable impact on many people’s quality of life. The BRC will identify markers and tools, which can be used to personalise treatment plans and identify opportunities to address unmet clinical need for patients suffering from complex wounds, psoriasis, hair loss and light-sensitive conditions.
Theme 5: Cancer Prevention and Early Detection
Lead: Professor Gareth Evans
Around 50% of people in the UK will be diagnosed with cancer in their lifetime. Cancer prevention and early detection strategies are not currently fully leveraged despite having an important role to play in the fight against cancer. The BRC will help to improve the targeting of these strategies, by developing the early markers needed to diagnose cancer sooner and rapidly identify whether treatment is having the desired response.
Theme 6: Advanced radiotherapy
Lead: Professor Catharine West
Radiotherapy has an important role to play in the fight against cancer. Around 40% of those patients cured of cancer have received radiotherapy as part of their treatment. The BRC will improve the delivery of radiation and develop markers to predict the benefit of different types of radiation and drug-radiation combinations, as well as the risk of long-term side effects,”
Theme 7: Cancer precision medicine
Lead: Professor Caroline Dive
The BRC will help the NHS to deliver a more personalised and proactive approach to caring for patients with cancer. Through the precise characterisation of tumours, its research will enable us to develop the diagnostic tests needed to match an individual’s cancer with the drug most likely to have the desired therapeutic effect. Work will also focus on helping clinicians to anticipate and appropriately manage drug resistant relapse, a common problem faced by patients with cancer. Musculoskeletal diseases